"In particular, his experience in UK-based telehealth and partnering with the NHS will be invaluable as ResApp expands its footprint into Europe."
It seems to me this appointment is strategically targeted for penetration into the UK NHS market. Dr Stein's appointment is preceded by an establishment of RAP wholly owned UK-based subsidiary barely a month ago.
I suspect RAP first contract outside Australia will be in the UK.
- Forums
- ASX - By Stock
- RAP
- Ann: ResApp Appoints Dr Michael Stein as a Non-Executive Director
Ann: ResApp Appoints Dr Michael Stein as a Non-Executive Director, page-23
Featured News
Add RAP (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, CEO
James Graham
CEO
Previous Video
Next Video
SPONSORED BY The Market Online